Recombinant P. aeruginosa ampC Protein, His-SUMO-tagged
Cat.No. : | ampC-1119P |
Product Overview : | Recombinant Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228) ampC Protein (27-397aa) was expressed in E. coli with N-terminal His-SUMO-tag. |
- Specification
- Gene Information
- Related Products
Source : | E. coli |
Species : | P. aeruginosa |
Tag : | His-SUMO |
Form : | Tris-based buffer, 50% glycerol. |
Molecular Mass : | 56.7 kDa |
AA Sequence : | GEAPADRLKALVDAAVQPVMKANDI PGLAVAISLKGEPHYFSYGLASKED GRRVTPETLFEIGSVSKTFTATLAG YALTQDKMRLDDRASQHWPALQGSR FDGISLLDLATYTAGGLPLQFPDSV QKDQAQIRDYYRQWQPTYAPGSQRL YSNPSIGLFGYLAARSLGQPFERLM EQQVFPALGLEQTHLDVPEAALAQY AQGYGKDDRPLRVGPGPLDAEGYGV KTSAADLLRFVDANLHPERLDRPWA QALDATHRGYYKVGDMTQGLGWEAY DWPISLKRLQAGNSTPMALQPHRIA RLPAPQALEGQRLLNKTGSTNGFGA YVAFVPGRDLGLVILANRNYPNAER VKIAYAILSGLEQQGKVPLKR |
Purity : | Greater than 90% as determined by SDS-PAGE. |
Storage : | The shelf life of liquid form is 6 months at -20 centigrade/-80 centigrade. The shelf life of lyophilized form is 12 months at -20 centigrade/-80 centigrade. |
Gene Name : | ampC beta-lactamase [ Pseudomonas aeruginosa PAO1 ] |
Official Symbol : | ampC |
Synonyms : | Beta-lactamase; ampC; EC= 3.5.2.6; Cephalosporinase |
Gene ID : | 878149 |
Protein Refseq : | NP_252799.1 |
UniProt ID : | P24735 |
Products Types
◆ Recombinant Protein | ||
ampC-4176E | Recombinant Escherichia coli ampC protein, His-SUMO-tagged | +Inquiry |
ampC-967E | Active Recombinant E. coli AmpC protein, His-tagged | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (26)
Ask a questionYes, there are certain species of bacteria that naturally produce AmpC beta-lactamases. Some examples include Enterobacter cloacae, Serratia marcescens, and Citrobacter freundii. These bacteria can carry AmpC genes in their chromosomal DNA, which allows them to express AmpC enzymes constitutively.
Yes, the spread of AmpC-mediated resistance is a global concern. It has been reported in various countries and is increasingly recognized as a significant threat to public health worldwide. The global nature of travel and international trade contributes to the dissemination of resistant bacteria, including those carrying AmpC genes. International collaboration and surveillance efforts are crucial to address this global problem effectively.
Yes, there is evidence of AmpC-mediated resistance being transmitted from animals to humans, particularly through the food chain. Bacteria carrying AmpC genes can be present in animals, such as poultry or livestock, and can be transferred to humans through contaminated food or direct contact.
Yes, horizontal gene transfer, which involves the transfer of genetic material between different bacterial strains or species, can contribute to the spread of AmpC genes. This can occur through plasmids, integrons, or transposons, facilitating the dissemination of antibiotic resistance.
Yes, overuse or inappropriate use of antibiotics can contribute to the development of AmpC-mediated resistance. The selective pressure exerted by antibiotics can promote the emergence and spread of bacteria with AmpC beta-lactamases, leading to the development of resistance.
Yes, AmpC-mediated resistance can often be associated with other resistance mechanisms, such as extended-spectrum beta-lactamase (ESBL) production or carbapenemases. Bacteria that produce AmpC beta-lactamases may also produce other enzymes that confer resistance to additional classes of antibiotics, further complicating treatment options.
There are several risk factors associated with acquiring AmpC-mediated resistance. These include previous exposure to antibiotics, particularly cephalosporins and beta-lactamase inhibitors; a history of hospitalization or healthcare-associated infections; prolonged hospital stays; invasive procedures; immunosuppression; and contact with AmpC-producing bacteria through contaminated environments or healthcare workers.
Healthcare professionals play a crucial role in preventing the spread of AmpC-mediated resistance. Measures that can help include appropriate antibiotic prescribing practices, adherence to infection prevention and control guidelines, strict compliance with hand hygiene protocols, proper disinfection and cleaning of equipment and environments, and active surveillance for multidrug-resistant bacteria.
AmpC beta-lactamases differ from other types of beta-lactamases in several ways. Unlike some other beta-lactamases, AmpC enzymes are not usually inducible. They are constitutively expressed at a basal level in certain bacterial species or can be upregulated in response to beta-lactam antibiotics. AmpC enzymes are not effectively inhibited by commonly used beta-lactamase inhibitors, unlike extended-spectrum beta-lactamases (ESBLs). Moreover, AmpC enzymes can hydrolyze a broad range of beta-lactam antibiotics, including third-generation cephalosporins and cephamycins.
Yes, the AmpC genes can be transferred between different bacterial species through horizontal gene transfer. This process allows the transfer of genetic material, including AmpC genes, from one bacterium to another, even across different species. This transfer can occur through plasmids, which are small, circular pieces of DNA that can replicate independently within bacteria.
AmpC-mediated resistance has become an increasingly prevalent concern in clinical settings. It has been reported in various healthcare-associated infections, including urinary tract infections, bloodstream infections, and pneumonia. The prevalence can vary geographically and among different healthcare facilities.
Yes, AmpC-mediated resistance can lead to treatment failures and poor clinical outcomes. Due to the ability of AmpC enzymes to hydrolyze a wide range of beta-lactam antibiotics, infections caused by AmpC-producing bacteria may be more challenging to treat. Limited treatment options may require the use of broader-spectrum antibiotics or combination therapies, which can increase the risk of side effects, antibiotic toxicity, and the emergence of further resistance.
Yes, research efforts are focused on developing novel antibiotics or modifying existing ones to specifically target AmpC beta-lactamases. These efforts aim to overcome AmpC-mediated resistance and improve treatment options for bacterial infections.
Yes, there are commercially available diagnostic tests that can detect AmpC-mediated resistance in clinical laboratories. These tests employ different methodologies, including enzyme-based assays or molecular techniques, to identify the presence of AmpC beta-lactamases in bacterial isolates.
The AmpC enzyme works by breaking down the beta-lactam ring structure of antibiotics, rendering them ineffective. This degradation occurs through hydrolysis, resulting in the inactivation of the antibiotics and making the bacteria resistant to their effects.
Developing new antibiotics is one approach to tackle AmpC-mediated resistance. However, it is a complex challenge as bacteria can develop resistance to new antibiotics over time. Therefore, a combination of strategies, including the development of new antibiotics and alternative treatments, is crucial to combat AmpC-mediated resistance effectively.
AmpC-producing bacteria can cause various types of infections, including urinary tract infections, bloodstream infections, intra-abdominal infections, pneumonia, and surgical site infections. The healthcare setting, particularly intensive care units and surgical wards, is more prone to AmpC-related infections due to higher antibiotic use, invasive procedures, and prolonged hospital stays.
Strains of bacteria expressing AmpC beta-lactamases pose a significant challenge in healthcare settings, as they are often resistant to a broad range of antibiotics, limiting treatment options. This can lead to more severe infections, increased healthcare costs, and higher mortality rates.
Various laboratory techniques can be employed to detect and monitor the presence of AmpC beta-lactamases in bacteria. These include phenotypic tests, such as the AmpC disk test or the AmpC E-test, as well as genotypic methods, such as polymerase chain reaction (PCR) or sequencing to identify specific AmpC genes.
The AmpC protein is primarily found in Gram-negative bacteria, including species like Escherichia coli and Klebsiella pneumoniae. It is a natural component of their resistance mechanisms.
Yes, the activity of AmpC can be modulated by different mechanisms. One notable mechanism involves the presence of regulatory proteins, such as AmpR, that control the expression of AmpC. Additionally, the activity of AmpC can be affected by mutations or changes in the regulatory regions of the gene.
AmpC-mediated resistance can sometimes go undetected through routine antibiotic susceptibility testing methods. This is because some AmpC enzymes are not effectively inhibited by commonly used beta-lactamase inhibitors, and their presence may not be evident. Specialized tests, such as AmpC disk tests or phenotypic confirmatory methods, are often needed to accurately detect and confirm AmpC-mediated resistance.
Yes, certain bacteria possess a regulatory system that can induce the production of AmpC in response to the presence of certain antibiotics, particularly beta-lactams. This adaptive response allows bacteria to develop resistance to these antibiotics.
Yes, several strategies have been proposed to overcome AmpC-mediated resistance. These include the use of combination therapy with inhibitors of AmpC enzymes, such as beta-lactamase inhibitors or the use of alternative antibiotics that are not susceptible to AmpC degradation.
Treatment options for infections caused by AmpC-producing bacteria can be challenging. In some cases, using antibiotics that are not susceptible to AmpC enzymes, such as carbapenems, may be effective. Combination therapy with a beta-lactamase inhibitor, such as clavulanate or tazobactam, along with another antibiotic, can also be considered.
Preventive measures to reduce the prevalence of AmpC-mediated resistance include promoting appropriate antibiotic use, implementing infection control practices in healthcare settings, and enhancing surveillance to detect and contain the spread of resistant bacteria. Additionally, responsible use of antibiotics in veterinary medicine and agriculture can also help reduce the prevalence in animals and prevent transmission to humans.
Customer Reviews (4)
Write a reviewwhen employed in Western Blotting experiments, the ampC protein consistently generates sharp and well-defined protein bands, enabling precise visualization and analysis of protein expression.
I highly recommend the use of the ampC protein in various experimental applications.
Considering its outstanding performance across multiple assays, I confidently endorse the inclusion of the ampC protein in diverse research studies.
the ampC protein has been successfully utilized in protein electron microscopy structure analysis, providing valuable insights into molecular structures and interactions.
Ask a Question for All ampC Products
Required fields are marked with *
My Review for All ampC Products
Required fields are marked with *
Inquiry Basket